Suppr超能文献

美国器官共享联合网络肾脏移植登记处。

The UNOS Renal Transplant Registry.

作者信息

Cecka J Michael

机构信息

UCLA Immunogenetics Center, Department of Pathology, University of California Los Angeles, Los Angeles, California, USA.

出版信息

Clin Transpl. 2002:1-20.

Abstract

Based upon data reported to the UNOS Renal Transplant Registry between 1998-2001, the overall one- and projected 10-year graft survival rates for 31,720 cadaveric kidney transplants were 89% and 51%, and for 14,162 living donor transplants they were 95% and 68%, respectively. These results represent improvements of 15% and 13%, respectively, over the 10-year graft survival rates reported for transplants performed during 1987-1989. Repeat kidney transplants accounted for 14% of deceased donor kidney transplants during 1998-2001 and the 3-year graft survival rates were significantly lower for second (77%) and multiply regrafted (73%) than for recipients of a first transplant (79%; p < 0.001). About 1,200 newly defined expanded criteria donor (ECD) kidneys were transplanted each year between 1998-2001. ECD kidneys represented 15% of deceased donor kidneys and yielded a significantly poorer 3-year graft survival rate (68%) and half-life (7.1 years) than kidneys from normal donors over age 5 (81% and 11.9 years; p < 0.001). The graft failure rates (censoring death with a functioning graft) were similar among recipients aged 31-50 and those aged 51-70 comparing both ECD and normal kidneys. The effect of HLA matching on kidney graft survival remains essentially unchanged after 30 years even with remarkable improvements in immunosuppression. Considering transplants performed between 1995-2001, matching for antigens at the HLA-A,-B, and -DR loci resulted in a 16% higher projected 10-year graft survival rate when compared with grafts mismatched for 5-6 HLA antigens (p < 0.001). The 10-year graft survival difference associated with HLA matching in US transplants performed between 1979-1984 and reported to the UCLA Registry before the introduction of cyclosporine was also 16%. The 3-year graft survival rates for zero HLA-DR mismatched normal kidney grafts (excluding ECD kidneys) were 83%, the same as for recipients of 0 HLA-BDR mismatched grafts. Those with one or 2 DR antigens mismatched had significantly poorer outcomes (80% and 77%, p < 0.001). Living donor transplants from offspring to parents and from genetically unrelated donors including spouses increased more than 5-fold since 1994. In 2001 the number of non-spouse unrelated donors surpassed the number of spouses (701 and 616, respectively). Despite the growing number of these HLA-disparate living donor transplants, their 3-year graft survival rates and half-lives remain as high as those for related donors sharing one HLA haplotype with the recipient. Laparoscopic donor nephrectomy now accounts for more than half of living donor surgeries reported to UNOS. There was no difference in graft survival or in early graft function associated with the type of donor surgery for 19,223 living-donor transplants between 1998-2001. Kidney transplants from non-heartbeating donors are beginning to increase and despite a significantly higher incidence of delayed function, 3-year graft survival rate was 79% for transplants between 1998-2001, the same as for conventional brain-dead deceased donor transplants.

摘要

根据1998年至2001年向美国器官共享联合网络(UNOS)肾脏移植登记处报告的数据,31,720例尸体肾移植的总体1年和预计10年移植肾存活率分别为89%和51%,14,162例活体供肾移植的相应存活率分别为95%和68%。这些结果表明,与1987年至1989年期间进行的移植手术所报告的10年移植肾存活率相比,分别提高了15%和13%。1998年至2001年期间,再次肾移植占死亡供者肾移植的14%,第二次移植(77%)和多次再移植(73%)的3年移植肾存活率显著低于首次移植受者(79%;p<0.001)。1998年至2001年期间,每年约有1200个新定义的扩大标准供者(ECD)肾脏被移植。ECD肾脏占死亡供者肾脏的15%,其3年移植肾存活率(68%)和半衰期(7.1年)明显低于5岁以上正常供者的肾脏(81%和11.9年;p<0.001)。在接受ECD肾脏和正常肾脏移植的31至50岁受者与51至70岁受者中,移植肾失功率(将有功能移植肾的死亡作为截尾)相似。即使免疫抑制有显著改善,HLA配型对肾移植存活的影响在30年后基本保持不变。考虑1995年至2001年期间进行的移植手术,与5至6个HLA抗原错配的移植肾相比,HLA - A、- B和 - DR位点抗原匹配的移植肾预计10年存活率高16%(p<0.001)。1979年至1984年在美国进行并在引入环孢素之前报告给加州大学洛杉矶分校登记处的移植手术中,与HLA配型相关的10年移植肾存活率差异也是16%。0个HLA - DR错配的正常肾移植(不包括ECD肾脏)的3年移植肾存活率为83%,与0个HLA - BDR错配的移植肾受者相同。有1个或2个DR抗原错配的受者结局明显较差(80%和77%,p<0.001)。自1994年以来,从子女到父母以及包括配偶在内的基因无关供者的活体供肾移植增加了5倍多。2001年,非配偶无关供者的数量超过了配偶的数量(分别为701例和616例)。尽管这些HLA不相合的活体供肾移植数量不断增加,但其3年移植肾存活率和半衰期仍与与受者共享一个HLA单倍型的亲属供者的存活率和半衰期一样高。现在,腹腔镜供肾切除术占向UNOS报告的活体供者手术的一半以上。1998年至2001年期间19,223例活体供肾移植中,与供者手术类型相关的移植肾存活或早期移植肾功能没有差异。来自非心跳供者的肾移植开始增加,尽管功能延迟的发生率明显较高,但1998年至2001年期间移植的3年移植肾存活率为79%,与传统脑死亡死亡供者移植相同。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验